Skip directly to content



Lee la Declaración Cero en español 

Leia a Declaração Zero em Portugues


Lisez la Déclaration Zéro en français

See current signatories.

July 22, 2012

We are a group of activists, clinicians, researchers, implementers, foundation and government officials, and policy makers who met in Cambridge, Massachusetts, from May 30 through June 1, 2012, to focus the world’s struggle against tuberculosis (TB) on achieving zero TB deaths, zero new TB infections, and zero suffering from TB.

We commit to zero TB deaths, zero new TB infections, and zero TB suffering and stigma, because:

  1. TB is preventable and curable.
  2. The main driver of today’s unnecessary TB deaths, new TB infections, and suffering and stigma is lack of political will.
  3. Every country in the world has the potential to reach the goal of zero TB deaths, zero new TB infections, and zero TB suffering and stigma.

This is a cry for global action against TB. We need a new global attitude in the fight against the disease. We need to change the way we have been thinking and working. We need to properly react against this biosocial disease of enormous and unacceptable magnitude that kills millions, unnecessarily, before our very eyes and that impoverishes and degrades the lives of millions more. We need to break with old approaches that have failed to rationally use the most effective approaches to combating the disease, and mobilize sufficient political will and resources to prevent needless transmission, sickness, and death. We can accept no less than zero new TB infections and deaths.

The immensity of the challenges posed by the increasing emergence and uncontrolled spread of drug-resistant forms of TB underlines the failure of the status quo. Too many cases TB are neither diagnosed nor treated in time to avoid onward transmission. Even when drug-resistant TB is diagnosed, too often local programs are not equipped to provide proper treatment or monitoring. Most new cases of drug-resistant (DR) TB occur from person-to-person spread; a June 2012 study from China indicates that one in 10 people with TB in China have multidrug-resistant (MDR) TB, one in 120 have extensively-drug resistant (XDR) TB, and most of these newly diagnosed cases have never been treated with second-line drugs. These data from the world’s most populous country support our demand for a radical change in the global approach to the TB pandemic; they demonstrate that efforts to control DR-TB solely focused on the highest-risk patients fail to detect most cases. Fewer than 3% of those currently diagnosed with TB have drug susceptibility tests (DST) performed, and fewer than 5% of persons with DR-TB receive appropriate, DST-guided therapy. The majority of DR-TB cases—whether diagnosed or not—receive no therapy or the wrong therapy. The TB status quo fails these individuals and exposes them and their communities to unacceptable risks of onward transmission, unnecessary suffering, and avoidable death.

We are committed to working with countries, policy makers, health and program managers, researchers, and activists, to achieve the political will necessary to obtain the most rapid and sustainable reductions in new TB infections and deaths in both adults and children with the goal of zero new TB infections and deaths.

No adult or child should die of TB, a disease that has been preventable and curable since the late 1940s. We cannot be satisfied with the realization of partial goals, such as that of reducing TB deaths by 50% compared with 1990, or simply reversing the epidemic, or with strategies that purport to lead to TB elimination by 2050—long after current leaders and policy makers will be retired or gone. Rather, we must commit to zero new TB infections and deaths.

Achieving zero TB is within our reach.

With currently available medications and empowered, functioning TB programs, 95% of the world's 9 million annual new cases of drug-sensitive (DS) TB can be cured. Of the 800,000 prevalent cases of multidrug-resistant MDR-TB, at least 70% can be cured. And of the 240,000 prevalent cases of XDR-TB, at least 30% can be cured. Thus, with sufficient political will to implement universal access to high-quality testing, treatment, and care, 8,172,000 (8.2 million) people can be cured each year. A substantial proportion of TB cases cannot be cured with currently available drugs. This is a consequence of neglect of basic, known strategies to successfully treat drug-susceptible TB and to prevent transmission of drug-resistant TB, and the disastrous neglect of the development of new TB drugs over the last 40 years. However, new TB treatment regimens now in development offer the hope of quicker, easier cures for both adults and children, regardless of TB drug resistance and HIV coinfection: at least six new drugs in four novel classes are in clinical trials today. It is likely that combinations of three or four of these new drugs can be used to treat and cure all forms of TB. 

However, without a simple, cheap point-of-care (POC) diagnostic test and early and appropriate treatment based on DST, the promise of these new drugs and regimens will be rapidly lost.

Intensified investment in tuberculosis research and development will be an essential element of getting to zero. The world spends less than one-third of the annual US$2 billion that the Stop TB Partnership estimates is required to discover and develop the new diagnostics, drugs, and vaccines necessary to fully eliminate TB. We recognize four critical requirements for reaching zero deaths, new infections, and suffering. First, the development and testing of a cheap, accurate, instrument-free POC diagnostic test for all forms of TB disease; second, safe and affordable shorter-course curative TB regimens to treat all forms of TB infection and disease; third, a successful TB vaccine; and fourth, all of these recommendations need to be supported by a commitment to social justice and to tackling directly the health and economic disparities that fuel the spread of TB worldwide. Governments in rich countries and those with large TB epidemics must rapidly intensify their investment in TB R&D. The goal of zero new TB infections and deaths increases the urgency for increased investment and more rapid development of new TB drug regimens, diagnostic tests, and vaccines.

Zero new infections.

One of the ages-old challenges of TB is its ability to cause a quiet infection without making that person actively sick. For some people, disease develops years later, allowing a TB outbreak to span generations. However, TB programs can interrupt this transmission by diagnosing every case of latent TB infection and every case of active TB disease. People with TB need affordable, accessible, POC diagnostic tests to detect TB and drug resistance in households and communities. We need to scale up availability of promising new rapid diagnostic tests by making them affordable and accessible in areas lacking electricity. Moreover, a true instrument-free, non-electric and cold-chain-dependent POC test is urgently needed to diagnose all forms of TB in adults and children, regardless of TB drug resistance and HIV coinfection.

Zero suffering.

TB attacks the most vulnerable. It is the leading cause of HIV-related morbidity and mortality, killing 350,000–450,000 people with HIV each year. Currently half of TB patients are tested for HIV, and half of HIV patients are screened and tested for TB. In coinfected patients, studies have proved that use of antiretroviral therapy significantly reduces TB infection in individuals and their communities, and reduces TB mortality. We must ensure that HIV-positive persons who are exposed to and infected by M. tuberculosis (but are not actively sick) receive lifesaving isoniazid preventive therapy (IPT) to prevent active TB. Getting to zero deaths means diagnosing and curing all cases of TB in people with HIV, and treating all cases of HIV in people with TB/HIV coinfection with immediate/early antiretroviral therapy (ART). Although some HIV medications cannot be taken with TB drugs, many available regimens can treat both diseases simultaneously. New TB drugs and regimens will help to alleviate this. Policy, program, and practice integration including HIV and TB diagnosis, treatment, and prevention is the best and most effective way to improve outcomes for both diseases, and needs to be accelerated globally.

People who are undiagnosed and untreated and those receiving TB treatment suffer from stigma, discrimination, job loss, and the inability to care and provide for family members. This loss reverberates through and adversely affects community and national productivity and economies. 

Since TB is transmitted exclusively by the airborne route, increased attention to and implementation of programs to reduce transmission by use of affordable and acceptable combinations of airborne transmission strategies are critically needed. This is a neglected area central to the reduction of TB infections and deaths, and requires combination interventions including BCG vaccination for infants, improved infection control in both health care and community settings, active case finding, treatment of latent infection, successful treatment of active disease, and cure.

We view the following elements as critical to achieving zero deaths, zero new infections, and zero suffering from TB:

I. Political Will and Commitment by Governments and Communities. Political will is the driving force that enables countries with high burdens of TB to reduce deaths, infections, and suffering. Commitment of other sectors of government beyond the health sector—and of society beyond government, including the private and nonprofit sectors, industry, and civil society—are instrumental in achieving these gains. We need to confront the social determinants of this disease that affects mostly the poor and marginalized and provide the dramatically increased resources critical to achieving this. Community engagement on all fronts is required to achieve zero TB deaths, zero new TB infections, and zero suffering from TB. For example,

  • The Republic of South Africa has endorsed the goal of zero TB deaths, new infections, and stigma in its 2012–2016 National Strategic Plan for AIDS, Tuberculosis, and Sexually Transmitted Infections.
  • The kingdom of Lesotho, which seven years ago lacked a functioning TB laboratory, has shown that a high-burden, low-income country can cure or complete treatment in 88% of its MDR-TB patients with zero loss to follow-up. Building on these regional successes, the Southern African Development Community (SADC) with support from many partners is rolling out plans for a subregional 14-country coordinated program to track and treat migrant workers, miners, and others who move among the 14 countries, using a health passport and common testing and treatment protocols.
  • The United States, which has endorsed a strategy of TB elimination, now enjoys, after twenty years of effort, the lowest TB rates in its recorded history. This is due to the combination of political commitment, active case detection and contact tracing, preventive therapy, well-functioning treatment programs with supervision, and universal access to drug-susceptibility testing, which permits universal access to and uptake of treatment regimens designed to cure TB regardless of the resistance profile.
  • Many other countries, particularly those in the middle-income range such as Brazil, China, India, Russia, and South Africa, have untapped ability to muster the political will necessary to reach zero new TB deaths, new infections, and suffering.

II. Active Case Detection and Elimination of TB Transmission. Since the 1990s, most TB programs around the world have focused on passive case detection of ill patients, many of these patients becoming progressively sicker for months. Without access to an accurate diagnosis, TB continues to be transmitted in health care, household, and community settings, including prisons, mines, and other crowded and unventilated places where people congregate. Failure to prevent transmission, and to diagnose infection and active disease early in the course of TB leads to worse outcomes including suffering and mortality, ongoing transmission, stigma, and discrimination. However, moving from passive to active case finding is feasible and acceptable to patients and communities, and will be critical to achieving zero new TB infections and deaths.

Recent results from the ZAMSTAR study in South Africa and Zambia have shown that household case finding with appropriate referrals can reduce TB by 22% in high HIV-prevalence rural and urban settings. The TB REACH initiative is proving that, by implementing innovative active case detection approaches, TB case detection among vulnerable population groups can be increased substantially. In a single year, TB REACH projects improved case detection by an average of 33%, and in some settings more than 100%. Pilot programs in rural South Africa demonstrate that integrated TB- and HIV community–based intensive case finding is feasible and acceptable and able to identify cases of HIV and both drug-sensitive and drug-resistant TB early in their course, even in remote and impoverished rural areas.

III. Family- and Community-Centered Care and Preventive Therapy to Block Onward Transmission. TB attacks the vulnerable. However, by empowering individuals and communities who can identify places where TB is transmitted and practice TB prevention strategies, every community can achieve universal case detection and contact tracing. Treatment to cure is also possible with universal drug susceptibility testing using validated rapid diagnostic tests. Cases should be detected within a month of symptom onset, and treatment started immediately and adjusted when the results of DST are available. Household, community, social networks, and occupational or correctional contacts (including children) of people with TB disease must be screened for active disease and latent TB infection and provided with appropriate treatment for TB or IPT. Many countries already acknowledge the importance of IPT in their guidelines, yet have still to implement them. 

Recent results from the THRio study conducted by the CREATE consortium show how it is possible to implement IPT in a high-burden, high-HIV-prevalence urban setting. Other strengths of the family- and community-centered care approach include assessing all family members and close contacts of infectious cases, universal referral to appropriate treatment and cure, universal prophylaxis where needed, reducing stigma, and permitting integration of other health services, including the prevention and treatment of other infectious diseases (including HIV and malaria) and noncommunicable diseases. Achieving zero requires proactive approaches to finding and treating children, pregnant women, and mothers, as well as marginalized populations such as prisoners, migrant workers, and drug users.

IV.Intensify TB Prevention, Care, and Treatment for Women and Children, Who Are Disproportionately Vulnerable. Maternal-child health programs and integrated management of neonatal and child illness programs are well-placed to better incorporate TB prevention, diagnosis, treatment, and cure as part of primary care.

Now, in 2012, the time is right to demand and to achieve zero deaths from TB, zero new infections, and zero suffering and stigma. It is high time to roll out known strategies and demand access to new medications, diagnostics, and vaccines in the development pipeline. We call on countries and communities everywhere to commit, with urgency and immediacy, to working for zero TB deaths, zero new TB infections, and zero TB suffering.

Join the movement!

Sign on as an individual.

Sign on as an organization.

For more information, send us an e-mail.

Organizational Signatories as of September 27, 2013:

A.O."Adolescentul", Moldova

Alliance to Control Tuberculosis (ACT), iNSPIRE R8, Philippines


Action Secours Ambulance (ASA), Haiti

Advanced Community Health Care Services Namibia (CoHeNa), Nambia

Africa Coalition on TB (ACT!), Africa

Africa Health Concern, Uganda

Aid Organization (AO), Bangladesh

AIDS Information and Support Center, Estonia

AIDS Tugikeskus (AIDS Information & Support Center), Estonia

Albert Einstein College of Medicine, USA

All-Party Parliamentary Group on Global Tuberculosis (UK Parliament), United Kingdom

Alternative for India Development, India

Área de Salud Integral, VIH/Sida e ITS de la Asociación LGBTI Algarabía, Spain

Arora's Healthcare and Education Foundation, Pakistan

Asociatia Obsteasca Tinerii pentru dreptul la viata (TDV), Moldova

Associacio de Planificacio Familiar de Catalunya i Balears, Spain

Association STOP TB Lithuania, Lithuania

Association d'Assistance au Developpement (ASAD), Cameroon

Association of Substitution Treatment Advocates of Ukraine (ASTAU), Ukraine

Aurum Institute, Johannesburg, South Africa

Bangladesh Lung Foundation, Bangladesh

Batho Pele Community Services Organisation, South Africa

Bathopele Community Service Organization, South Africa

Baylor Black Sea Foundation (FBMN), Romania

Bill Sullivan-Ray of Hope Foundation, USA

Blossom Trust, India

Bureau d'Etude pour la Formation, l'Organisation, la Recherche Conseils en Entreprise, Burkina Faso

Case Western Reserve University, TB Research Unit, USA

Center for Health Policy and Studies (PAS Center), Moldova

Center for Research Excellence in Tuberculosis, Australia

Centre for Youth Development and Social Empowerment (CYDSE), Malawi

Centro de Educação Sexual (CEDUS), Brazil

Centro de Promoção da Saúde, Brazil

Centrul EducaţionalAlcoolismul i Narcomania, Moldova

CF Virtus, Ukraine

Chanchal Janakalyan Samity, India

Charitable organization Maybutne Club, Ukraine

Chichetkelo Outreach Partners, Zambia

Coalition of People Fighting HIV/AIDS, TB and Malaria in Kenya (COPFAM), Kenya

Comitè Primer Desembre-Plaaforma Unitària d'ONG-Sida de Catalunya, Spain

Communicable Diseases Unit, HMC, Qatar

Community and Family Aid Foundation, Ghana

Community Initiative for TB, HIV/AIDS & Malaria (CITAM+), Zambia

Consortium to Respond Effectively to the AIDS-TB Epidemic (CREATE), USA

Copilărie pentru toți, Moldova

Credinta, Moldova

Department of Global Health and Social Medicine, Harvard Medical School, USA

Desmond Tutu TB Centre, South Africa

Division of Leprosy, TB and Lung Disease, Kenya

Drustvo SKUC, Slovenia

Emmanuel Hospital Association, India

Environment Protection for Rural Development Organisation (EPRUDO), Uganda

Estonian Network of PLWH, Estonia

European AIDS Treatment Group (EATG), Belgium

Farijika Support Group, Kenya


Friends of Suffering Humanity, Ghana

Fundação Ataulpho de Paiva - FAP Liga Brasileira Contra a Tuberculose, Brazil

Fundación para Estudio e Investigación de la Mujer-FEIM-, Argentina

Furum ONGs Tuberculose RJ, Brazil

GHE, England

GIC CADIRE, Cameroon

Global Alliance for TB Drug Development, USA

Global Health Advocates, France

Global Tuberculosis Community Advisory Board (TB CAB), International

Good Health Educators Initiative, Nigeria

Grupo de Apoio a Prevençao da AIDS, Brazil

Grupo de Trabajo sobre Tratamientos del VIH (gTt), Spain

Hamara Healthy Living Centre, Leeds, United Kingdom

Healthy Options Project Skopje (HOPS), Macedonia

HIV and AIDS Care and Support Association (HACSA), Siera Leone

HIV i-Base, United Kingdom

Hope Care Foundation, Ghana

Hope for Future Generations, Ghana

Instituto de Medicina Tropical Alexander von Humboldt, Peru

Integrated Development in Focus, Ghana

Interactive Research and Development (IRD), Pakistan

International Community of women living with HIV Eastern Africa, Uganda

International Union Against Tuberculosis and Lung Disease (The Union), France

JAGGARTA Organization, Pakistan

Janssen Research & Development, LLC, USA

Japan Anti-Tuberculosis Association, Japan

Jhpiego, an affiliate of John Hopkins University, Mozambique

Johns Hopkins University Center for Tuberculosis Research, USA

Journal Du Peuple, Benin

Journalists Against TB, India

Kaneka Rural Clinics Advisory and Nutritional Centers, Kasese (KARUCAN), Uganda

Kenya Association for the Prevention of TB and Lung Diseases (KAPTLD), Kenya

Kenya Legal & Ethical Issues Network on HIV & AIDS (KELIN), Kenya

KNCV Tuberculosis Foundation, the Netherlands

Labatec Pharma S.A., Switzerland

Laboratorio Nacional de Referencia da Tuberculose, Mozambique

Liga Científica de Tuberculose do Rio de Janeiro, Brazil

Lucane Pharma, France

Mapambano ya Kifua Kikuu na Ukimwi Temeke (MUKIKUTE), Tanzania

Mission of Grace Ministries, Ghana


Nationa Empowerment Network of People living with HIV/AIDS in Kenya (NEPHAK), Kenya

National Tuberculosis Control Program, Mozambique

Nava Kiran Plus, Nepal

Nepal Anti-Tuberculosis Association (NATA), Nepal

New Dawn of Hope, Zimbabwe

New Jersey Medical School Global Tuberculosis Institute, USA


NGO Union of PLHIV, Russia

NGO Volunteer, Tajikistan

NGO Opcija Ohrid, Makedonija

Nonprofit Organization of Social Support of the Population "Project April", Russia

Observaturio Tuberculose Brasil, Brazil

Paneer HIV Positive Women Network Trust, India

Partners In Health (PIH), USA

PASADA, Tanzania

People Empowerment Organization (PEO), Nigeria

Pitjeng Foundation, South Africa

PLAN Health Advocacy and Development Foundation, Nigeria

Planeta Salud, Spain

Positive People Armenian Network, Soc. NGO, Armenia

Positive-Generation/Cameroon, Cameroon

PRANTIK Manobik Unnoyan Kendra, Bangladesh

Professionals For Humanity (PROFOH), Nigeria

Project Concern International (PCI), USA

Project HOPE/USAID Quality Health Care Project, Kyrgyzstan

Projeto Riscobiologico, Brazil


Public organization "SPIN Plus"/Общественная организация "СПИН Плюс", Tajikistan

Public Organization "TRUST+", Tajikistan

Rainbow TB Forum (Affected Community), India

Real Opportunities Network (formerly Reliance Network), Ghana

REDE TB, Brazil

Réseau des femmes en action pour le développement social REFEADES -MAKOBOLA, DRC

RESULTS International, Australia

RESULTS UK, United Kingdom

Riders for Health, South Africa

Rural-Urban Women And Children Development Agency (RUWACDA), Ghana

Sairam Health Care Charitable Trust, india

Secretaria Municipal de Saude e Defesa Civil do Rio de Janeiro, Brazil

Sentinel Project on Pediatric Drug-Resistant Tuberculosis, USA

Sequella Inc., USA

Sewa Development Trust Sindh (SDTS), Pakistan

Shwaas Center,   Navkar Hospital, India

Sinza Youth Peer Educators, Tanzania

SNEHA Foundation, India

Society Association HIV.LV, Latvia

Society for Health & Education Development (SHED), Pakistan

Society of Social Networking for Education, Health & Agriculture (SNEHA), India

Somali Welfare Organization (SWO), Somalia

South African National Tuberculosis Association JHB Branch, South Africa

St Francis Health Care Services, Uganda

Stop TB Partnership Working Group on New Drugs, USA

Stop Tuberculose BOUAKE, Cote D'Ivoire

Suvadi Inc., Sri Lanka

Swiss Tropical & Public Health Institute, Switzerland

Sydney Emerging Infections and Biosecurity (SEIB), Australia

Talaku Community based Organization, Kenya

Tamil Nadu State Aids Control Society (TANSACS), India

TB Action Group, Kenya

TB Action Group (TBAG), United Kingdom

TB Alert, United Kingdom

TB Centre, London School of Hygiene and Tropical Medicine, United Kingdom

TB Europe Coalition, Belgium

TB Investigation Unit of Barcelona, Spain

TB Network Oyo State Chapter, Nigeria

TB Proof, South Africa

TB/HIV Care Association, South Africa

TBmanifesto - a division of FSmanifesto, Saudi Arabia

Thai AIDS Treatment Action Group (TTAG), Thailand

The AIDS Support Organisation (TASO), Uganda

The Centre for Research Excellence in Tuberculosis, Sydney, Australia

The Lancet, United Kingdom

The Norwegian Heart and Lung Patient Organization (LHL), Norway

The Tuberculosis Survival Project, United Kingdom

The University of Sydney, Australia

Tineretul Pozitiv (Позитивная Молодежь), Молдова

Treatment Action Group (TAG), USA

Tuberculosis Advocacy Consortium, Kenya

Tuberculosis Association of Kerala, India

UK Coalition to Stop TB, United Kingdom

Universal Versatile Society, India

Vijana Amani Pamoja, Kenya

Vivir. Participacion, Incidencia y Transparencia, A.C., Mexico

Women and Youth Development Initiatives (WOYODEV), Nigeria

Womenplus Against TB and HIV in Kenya, Kenya

World Vision, Canada

World Vision, USA

Wote Youth Development Projects, Kenya

Благотворительная организация "Всеукраинская Лига "Легалайф", Украина

Благотворительный Фонд " Вектор допомоги", Украина

Вінницьке обласне відділення ВБО "Всеукраїнська мережа ЛЖВ", Україна


Кировоградская областная благотворительная организация "Открытое сердце", Украина

Кировоградское областное отделение ВБО "Всеукраинская сеть ЛЖВ", Украина

Криворожское городское отделение Всеукраинской благотворительной организации "Всеукраинская сеть людей живущих с ВИЧ", Украина

Луганское областное отделение Всеукраинской благотворительной организации "Всеукраинская сеть людей живущих с ВИЧ/СПИД", Украина

Марворид, Душанбе, Таджикистан

Медицинское Управление Департамента Пенитенциарных Учреждений Министерства Юстиции, Республика Молдова

Международный благотворительный фонд "Вертикаль", Украина

Национальная Сеть Ассоциация "Единство людей, живущих с ВИЧ", Кыргызстан

НПО "ДИНА", Республика Таджикистан

Общественная организация "Центр демократического развития", Украина

Общественный Фонд "Здоровье для всех", Кыргызстан

ОМО "Клуб взаимопомощи "Жизнь+", Украина

ОО "Доверие+", Таджикистан

ООО "Волонтёр", Республика Таджикистан

ОЮЛ "Ассоциация СПИД-сервисных НПО Кыргызской Республики "АнтисПИД"", Кыргызстан

ПМ БО "Обериг", Украина

Сообщество ЛЖВ, Узбекистан

Черкасское областное отделение ВБО "Всеукраинская Сеть ЛЖВ", Украина

ЧОГО "Позитивне життя", Україна

эстонская сеть людей живущих с вич, эстония



Individual Signatories as of November 12, 2013:

Sufyan Abdulber, Federal Ministry of Health, Ethiopia

Hussein Abdur-Razzaq, Lagos State TB and Leprosy Control Programme, Nigeria

Saddiq Abdurrahman, Department of Public Health, Health and Human Service, Abuja, Nigeria

Ajoke Adagbada, Nigeria

Rowena Aguilar-Sino, Australia

Sarita Aguirre García, Programa Nacional de Control de la Tuberculosis, Paraguay

Koldo Aguirrebengoa, Osakidetza-Servicio Vasco de Salud, Spain

Faiz Ahmad Khan, McGill University, Canada

Zeeshan Ahmed, Lady Reading Hospital Peshawar, Pakistan

Heather Alcock, United Kingdom

Nunuu Ali, Ministry of Health - Pemba, Tanzania

Nyende Ali, St Francis Health Care Services, Uganda

Tânia Almeida, Universidade do Estado do Rio de Janeiro, Brazil

Pedro Almeida Da Siva, Universidade Ferederal Do Rio Grande - Furg, Brazil

Andrei Altdorf, Convictus Estonia, Estonia

Ivana Alvarez, University of Buenos Aires, Argentina, Argentina

Erika Alves, Brazil

Farhana Amanullah, Indus Hospital TB Program and International Research and Development, Pakistan

Doug Anderson, Australia

Emmanuel André, Uclouvain & Interactive Research and Development, Belgium/DRC

Petre Angelov, ZONA - Kavadarci, Macedonia

Marg Angliss, Australia

Koya Anil, TB Alert India, India

Nebreda Anna, Spain

Mercy Annapoorni, India

Oleg Antipin, Credinta, Moldova

David Apasera, Ghana

Francis George Apina, Network of Men Living with HIV and AIDS in Kenya (NETMA+), Kenya

Jucara Arabe, Instituto de Pesquisa Clinica Evandro Chagas (IPEC-FIOCRUZ), Brazil

Carla Araujo, Universidade Federal do Rio de Janeiro (UFRJ), Brazil

Heidi Arnel, Australia

Alla Asaeva, FAR, Russia

Alena Asaeva, Russia

Achidi Asanga Zaccheus, National TB Control Program (NTP), Cameroon

Janna Ataiants, USA

Rifat Atun, Imperial College, London, United Kingdom

Christian Auer, Swiss Tropical and Public Health Institute, Switzerland

Yu Nandar Aung, Sydney Medical School, Myanmar

Ayodele Awe, World Health Organization, Abuja, Nigeria

Margaret May Baekalia, Fiji

Samir Bahnasy, Pulmonary Rehablitation Center, MOH, Kuwait, Kuwait

Sheila Balis, Australia

Maradona Barbosa, Brazil

Antigone Barton, Center for Global Health Policy, USA

Aparna Barua , RESULTS, United Kingdom

Anton Basenko, Association of Substitution Treatment Advocates of Ukraine, Ukraine

Mercedes Becerra, Harvard Medical School, USA

Vikarunnessa Begum, World Health Organization (WHO), Bangladesh

Sue Bentley, Australia

Vineet Bhatia, India

Carmelita Biagtan, The Lung Association of British Columbia, Canada

Roy Bishop, Australia

Gill Black, Sustainable Livelihoods Foundation , South Africa

Kate Bocca, Australia

Celina Boga, Fundação Oswaldo Cruz (FIOCRUZ), Brazil

Ana Maria Bontempo Dias, Brazil

Buzz Borsitzky, Australia

Adedayo Bose, DOTS provider, Nigeria

Kolleen Bouchane, RESULTS, USA

Louise Bourchier, Australia

Sara Bowsky, USAID, Mozambique

Rebecca Broumos, Australia

Douglas Bruce, Yale School of Medicine, USA

Denise Bryant, Australia

David Bryden, RESULTS, USA

Jeff Buck, China

Inga Bulotien, Lithuania

Maxwell Burnet, Australia

Lia Burns, Australia

Dickens Bwana, Mukikute TB Patient Organization , Tanzania

Natalie Caldwell, Australia

Jennifer Callaway, Australia

Frank Calver, Australia

Bonnie Cameron, Australia

Laura Campbell, USA

Tatiana Pacheco Campos, Brazil

Natasha Candreva, Brazil

Tom Carter, Australia

Noel Cass, Australia

Gail Cassell, Department of Global Health and Social Medicine Harvard and Infectious Disease Research Institute Seattle, USA

Ana Maria Castro, Secretaria Municipal de Sa˙de e Defesa Civil, Brazil

Solange Cavalcante, Fundação Oswaldo Cruz (FIOCRUZ); Rio de Janeiro Health Department, Brazil

Merce Cazes, Spain

Paula de la Certa, Spain

Richard Chaisson, Johns Hopkins University School of Medicine, USA

Jeremiah Chakaya, National TB Control Programme, MoH Kenya, Kenya

Yrlene Cherques, Brazil

Catherine Cherry, Australia

Lucy Chesire, TB Advocacy Consortium , Kenya

Eric Chikukwa, New Dawn of Hope, Zimbabwe

Olga Chilcevschi, Credinta, Moldova

Sunayan Chowdhury, India

Gavin Churchyard, Aurum Institute, South Africa, South Africa

Aliona Ciobanu, Мололеж за право на жизнь, г.Бэлц,Молдова

Manfred Claasz, Australia

Gaël Claquin, Mozambique

Polly Clayden, HIV i-base, United Kingdom

Helen Clegg, United Kingdom

Geoff Clifford, Australia

Adrian Clifford, Australia

Ted Cohen, Brigham and Womens Hospital, USA

Alberto Colorado, Advocates for Health International, USA

Luc Comhaire, Damien Foundation Belgium, Belgium

Hugo Cornejo, Direccion Regional de Salud Lima, Peru

Marylia Costa, Australia

Zehelio Costalunga, Rede Nacional de Ensino e Pesquisa (RNP), Brazil

Denise Cotrim da Cunha, Brazil

Gaoussou Coulibaly, Stop Tuberculose Bouake, Cote d'Ivoire

Neyse Couto, Brazil

Greg Croke, Australia

Luiza Cromack, Brazil

Zaina Hamunza Mutualo Cuna, Jhpiego,an affiliate of John Hopkins University, Mozambique

Zoe Cutcher, Australia

Jaqueline Aparecida da Rosa, Apoio,Solidariedade e Prevenção à Aids (ASPA), Brazil

Margareth Dalcolmo, Brazil

Charles Daley, National Jewish Health, USA

Peter Daley, Memorial University, Canada

Jean Dandois, Damien Foundation , Belgium

Doughman Danielle, USA

Colleen Daniels, Treatment Action Group (TAG), USA

Pamela Das, The Lancet, United Kingdom

Regina Daumas, Fundação Oswaldo Cruz (FIOCRUZ), Brazil

Aurora Dawson, TB ALERT/ TBAG, United Kingdom

Isadora De Backer, Damien Foundation, Belgium

Nikos Dedes, Positive Voice, Greece

Maria Jose del Pino, Spain

Tine Demeulenaere, Damien Foundation, Belgium

Anne Detjen, International Union Against Tuberculosis and Lung Disease (IUATLD), North America

Espe Devesa, Spain

Brett Dickson, International Organization for Migration (IOM), Cambodia

Vanja Dimitrievski, Healthy Options Project, Macedonia

Lucica Ditiu, Stop TB Partnership (STBP), Switzerland

Hedwin Kitdorlang Dkhar, Institute of Microbial Technology, India

Susan Dorman, Johns Hopkins Medical Institute and Johns Hopkins Bloomberg School of Public Health, USA

David Dowdy, Johns Hopkins Medical Institute and Johns Hopkins Bloomberg School of Public Health, USA

Benjamin Dzivenu Tsikata, Hope Care Foundation, Ghana

Cordula E., Take That TB, Germany

Sales Eduard, Particular, Spain

Wafaa El-Sadr, Columbia University, USA

Tambo Ernest, Cameroon

Peter Escott, Australia

Antonieto S. Evangelista, Alliance to Control Tuberculosis (ACT) - INSPIRE R8 , Philippines

Christine Evans, Australia

Margaret Evans, Australia

Aleksandr Ezdakov, Russia

Jum'atil Fajar, Informasi Kapuas, Indonesia

Anne Fanning, Stop TB Partnership (STBP), Canada

Nadja Faraone, Brazil

Roger Fernando, Australia

Rayane Cupolillo Ferreira, Brazil

Gerson Filho, Escola Nacional de Saude Publica (ENSP), Brazil

Laia Fina, Unitat d'Investigació en Tuberculosi de Barcelona, Spain

Mary Lou Fisher, USA

Joseph Fitchett, London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom

tania Flavell, Australia

Esther Flores Fuentes, Direccion Regional Salud Ica Equipo tecnico de la Estrategia de Prevencion y Control de la Tuberculosis, Peru

Underwood Frank, National TB Program, Fiji

Tim Fricke, Australia

Gerald Friedland, Yale School of Medicine, USA

Elaine Fung, Australia

Jennifer Furin, Case Western Reserve University, USA

Alaa Gad, ARMH, Saudi Arabia

Julie Gallard, Australia

John Ganey, Fairfax County Health Department, USA

Nathalie Garon, Canada

Nathan Geffen, Treatment Action Campaign (TAC), South Africa

Charlotte Gesell, First Nations Inuit Health Branch, Health Canada, Canada

Katherine Gibney, Australia

Merle Gilbo, Australia

Cristiane de Cassia Duarte da Silva Godinho, Brazil

Marcelo Bondi Godinho, Brazil

Jonathan Golub, Johns Hopkins Medical Institute and Johns Hopkins Bloomberg School of Public Health, USA

Patrick Gomani, Partners in Health, Malawi

Marco Gomes, Canada

Vuyokazi Gonyela , Treatment Action Campaign (TAC), South Africa

Julian Gonzalez-Martin, Hospital Clinic of Barcelona-University of Barcelona, Spain

Fred Gordin, George Washington University, USA

Rebecca Gordon, Australia

Eduardo Gotuzzo, Universidad Peruana Cayetano Heredia, Peru

Celine Gounder, Bureau of TB Control, NYC Dept of Health and Mental Hygiene, USA

Charlotte Goyon, Global Health Advocates, France

Hamish Graham, Australia

Ria Grant, TB HIV Care Association, South Africa

Maureen Grant, Australia

Jodie Griffin, Australia

Bogdan Grigoriu , University of Medicine and Pharmacy, Dept of Pulmonology, Romania

Uta Grosse, Kings College London, United Kingdom

Belle Groves, Australia

Maíra Guazzi, Secretaria Municipal de Saúde e Defesa Civil/ Programa de Controle da Tuberculose (SMSDC/PCT) , Brazil

Wanda Guimaraes, Centro de Promoção da Saúde (CEDAPS) , Brazil

Shobhana Gurung Pradhan, Britain Nepal Medical Trust, Nepal

Vanessa Gutierrez Baena, Colombia

Silje Hagerup, Norwegian Heart and Lung Patient Association (LHL), Norway

Ameer Haider Babbar, JAGGARTA Organization, Pakistan

Jan Hajek, Canada

Bev Hall, Australia

Bev Hall, Australia

Thein Han, Myanmar

Kate Hardie, Australia

Joshua Hardy, Australia

John Harrison, Australia

Boom W. Henry, TB Research Unit, Case Western Reserve University, USA

James Herlihy, Australia

Roberto Hermida, Spain

Anneke Hesseling, Desmond Tutu TB Centre, South Africa, South Africa

Richard Hill, Australia

Molly Holshouser, Center for TB Research, Johns Hopkins University, USA

Timothy Holtz, Doctors for Global Health, USA

Robert Horsburg, Boston University School of Public Health, USA

Benjamin Horsman, Visual Epidemiology Project,

Erin Howe, USA

Jennifer Hughes, Médecins Sans Frontières (MSF), South Africa

Gwen Hughes, Australia

Rebecca Hurley, Australia

Rocio Hurtado, Brigham and Womens Hospital, USA

Khanh Huyen Pham, World Health Organization Representative Office in VietNam, Viet Nam

Stephen Hyams, Australia

Maria-Jose Iglesias, Universidad Zaragoza, Spain

Maryrose Baby Ikumi, Kenya

Mel Ireland, Australia

Rania Ismail, Jordan

Giselle Israel, Health Department of Rio de Janeiro City, Brazil; CREATE, Brazil

Ivetta Izhora, Australia

Hristijan Jankuloski, Healthy Options Project Skopje (HOPS), Macedonia

Ernesto Jaramillo, World Health Organization (WHO), Colombia

Coco Jervis, Treatment Action Group (TAG), USA

Moratoa Joale, Health Sciences Student Council, University of Cape Town, South Africa

Jay Johnston, University of British Columbia, Canada

Phyllis Jones, Australia

Phyllis Jones, Australia

Cleverson José Bezerra Guedes, Universidade Estadual de Maringá, Brazil

Bertrand Kampoer, FISS-MST/SIDA, Cameroon

Joyce Kamwana, Coalition of Women Living with HIV and AIDS, Malawi (COWLHA), Malawi

Stacy Kancijanic, University Research Co., LLC (URC),

Sandra Kanck, Australia

Karyn Kaplan, Treatment Action Group (TAG), USA

Saroj Kumar Kar, India

Samayog Karmacharya, UNICEF, DPRK

Vazha Kasrelishvili, Center for Information and Counselling "TANADGOMA", Georgia

Chris Kennedy, Australia

Mandy Kennedy, Australia

Vivienne Kernohan, Zimbabwe

Salmaan Keshavjee, Harvard Medical School, USA

Aamir Khan, Interactive Research and Development (IRD), Pakistan

Afshan Rahim Khan, Pakistan

Saira Khowaja, Interactive Research and Development (IRD), Pakistan

Zara Kimpton, Australia

Mette Klouman, Norwegian Heart and Lung Patient Organisation (LHL), Norway

Serena Koenig, Brigham and Women's Hospital, Harvard Medical School, USA

Nick Koletsas, Australia

Anna Koshikova, All-Ukrainian Network of PLWH, Ukraine

Alyson Kosina, Australia

Koot Kotze, TB Proof, South Africa

Kavitha Krishnan, Australia

Sushena Krishnaswamy, Australia

Jessica Kuehne, RESULTS , United Kingdom

Indrajit Kumar, India

Blessina Kumar, India

Vadim Kurganov, Estonia

Alexey Kvitkovskiy, The Association of Substitution Treatment Advocates of Ukraine (ASTAU), Ukraine

Egidio Langa, Ministry of Health, Mozambique

Betsy Leary, Australia

Philip Lederer, USA

Zinabwa Legesse, Australia

Marlene Paulino Rodrigues Lene, Espaço prevenção /saúde DSTS/AIDS/TB/PV Mope liderança Marlene Paulino, Brazil

Montse León, Spain

Helen Lescesen, Australia

Tessa Letcher, Australia

Pamela Lewis, Lucane Pharma, France

Deborah Lewis, Australia

Genevieve Lilley, Australia

Vanessa Linde, Australia

Raul Lindemann, Estonian Network of People Living with HIV (EHPV), Estonia

Vika Lintsova, Ukraine

Line Lismont, Belgium

Mark Lobato, New England TB Consortium, USA

Laila Løchting, Norwegian Heart and Lung Patient Organisation (LHL), Norway

Simon Logan, All-Party Parliamentary Group on Global Tuberculosis , United Kingdom

Christine Lubinski, Infectious Diseases Society of America, USA

Ilie Macovei, Viata Noua, Moldova

Okechukwu Madukwe, Ministry of Health Abia State , Nigeria

Asif Mahmud, Institue of Epidemiology, Disease Control and Research (IEDCR), Bangladesh

Allan Maleche, Kenya Legal & Ethical Issues Network on HIV & AIDS (KELIN), Kenya

Pierre Mambrini, Lucane Pharma, France

Vinicio Nicolas Mancheno Carrillo, Red internacional de organizaciones en Salud, Ecuador

Judith Mandelbaum-Schmid, Stop TB Partnership, Switzerland

Shamim Mannan, India

Armando Mantoano, Brazil

Ben Marais, University of Sydney, Australia, Australia

Jonathan Mark, Papua New Guinea

Suzanne Marks, USA

Paulino Rodrigues Marlene, Espaço prevenção /saúde DSTS/AIDS/TB/PV Mope liderança Marlene Paulino, Brazil

Laura Martin, RESULTS Educational Fund/ ACTION, USA

Arikana Massiah , University College London , England

Amos Mataruse, Mozambique

Rebecca Mathews, Australia

Momar Talla Mbodji, Plan International, Senegal

Karen McComiskey, Australia

Amy McConville, TB Action Group, United Kingdom

David McDonald, Australia

Noela McDonald, Australia

Jo McElhinney, Australia

Lindsay McKenna, Treatment Action Group (TAG), USA

Sue McMullen, Australia

Ellen McNeice, Australia

Ruth McNerney, United Kingdom

Mteto Kidwell Mfikili, Bambisnani Project, South Africa

Guillamón Peris Miguel Ángel, Spain

William Miles, Australia

Ann Miller, Harvard Medical School, USA

Ann Miller, Australia

Jennifer Mills, Australia

Margot Milne, Australia

Mayank Mohan Mishra, Society of Social Networking for Education, Health & Agriculture (SNEHA), India

Pushpdeep Mishra, Open Source Drug Discovery, India

Samuel Misoi, Ministry of Public Health & Sanitation, Division of Leprosy, TB & Lung Disease, Kenya

Michael Mitchell, Australia

Carole Mitnick, Harvard Medical School, USA

Rostislav Mitrofanov, Novosibirsk TB Research Institute, Russia

Subrat Mohanty, The UNION South-East Asia Regional Office, India

Rendi Moke, World Vision International, Papua New Guinea

Jorge Molina, Red Internacional de Organizacion de Salud , Ecuador

Aleksandrs Molokovskis, Latvia

Cèsar Mombunza , CONERELA+, Democratic Republic of the Congo

Timothy Moore, Australia

Mara E. Martinez Morant, Spain

Yulya Moskvina, Russia

Kirsten Muir, Australia

Felister Mutoka, Kenya Ethical and Legal Issues Network on HIV/Aids, Kenya

Nigor Muzafarova, Technical Officer, GDF, Tajikistan

Sharon Nachman, HSC SUNY Stony Brook, USA

Carol Nacy, Sequella, Inc., USA

Mohammad Hasan Namaei, Birjand University of Medical Sciences, Iran

Dorothy Namutamba, International Community of Women Living with HIV- Eastern Africa, Uganda

Dorothy Namutamba, International Community of Women Living with HIV Eastern Africa, Uganda

Edward Nardell, Partners In Health, Harvard Medical School, Brigham & Women's Hospital, USA

Voskre Naumoska Ilieva, Healthy Options Project Skopje (HOPS), Macedonia

Silvana Naumova, Macedonia

Cecilia Nawavvu, Makerere University Joint AIDS Program, Uganda

Enouce Ndeche, Vijana Amani Pamoja , Kenya

Nguyen Viet Nhung, National TB Control Program (NTP), Vietnam

Johanna Nice, USA

Fe Nocete, German Doctors for Developing Countries, Inc., Philippines

Dannialle Norman, Australia

Emily Nyagaki, Kenya Association for the Prevention of Tuberculosis and Lung Diseases (KAPTLD), Kenya

Carol Nawina Nyirenda, Community Initiative for TB, HIV/AIDS & Malaria (CITAM+), Zambia

Sharon O'Boyle, Australia

Rick O'Brien, Self-employed TB consultant, USA

Neil O'Brien-Simpson, Australia

Michelle O'Dea, Australia

Helen O'Dea, Australia

Liam O'Doherty, Australia

Max O'Donnell, Albert Einstein College of Medicine, USA

Joanne O'Neill, Australia

Huaman Soldevilla Obdulia, Direccion Regional de Salud-Ayacucho, Peru

Matthew Ogunmodede, Community Health Information, Advocacy and Right Initiative (CHIARAI), Nigeria

Prosper Okonkwo, AIDS Prevention Initiative, Nigeria, Nigeria

Svitlana Okromeshko, PATH, USA

Obatunde Olubunmi Oladapo, PLAN Health Advocacy and Development Foundation, Nigeria

Alexandre Oliveira, Universidade Federal do Rio de Janeiro (UFRJ), Brazil

Vincent Olughor, MDR-TB Unit, University College Hospital Ibadan, Nigeria

Sandra Opoku, Australia

Gloria Oramasionwu, Atlanta, GA, USA

Peter Owiti, Wote Youth Development Projects, Kenya

Peter Owiti, Wote Youth Development Project, Kenya

Carolina Pacheco, Brazil

Nesri Padayatchi, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Alice Pallid, Australia

Martin Pan, United Kingdom

Dimitrios Papaventsis, Reference Laboratory for Mycobacteria, Sotiria Chest Diseases Hospital, Athens, Greece

Ehtiram Pashayev, Public Union Against AIDS, Azerbaijan

Corey Peak, Harvard School of Public Health, USA

Paula Perdigão, Mozambique

Sara Perea Moreno, Socios en Salud Sucursal Peru, Peru

Claudia Pereira, Brazil

Jorge Alberto Perez, Spain

Virginia Perrucho, Comitê de Combate a Tb da Região Metropolitana de Salvador e HEOM , Brazil

Marcia Perry, Australia

Anastassia Peterson, Estonian Network of People Living with HIV, Estonia

Raquel Piller, Secretaria Municipal de Saude Rio de Janeiro, Brazil

Ana Gloria Pires, Bem-Estar Familiar no Brasil (BEMFAM), Brazil

Luis Portal, CONAPESALUD, El Salvador

Matt Price, Harvard School of Public Health, USA

Svetlana Prosvirina, Non-Governmental Organization "STATUS PLUS", Russia

Prem Raj P Pushpakaran, National Institute of Technology, Calicut, India

Rubens Raffo, Fórum de ong aids do RS- Brasil, Brazil

Kathryn Rainsford, Australia

Mario Raviglione, Italy

Akhilesh Rawat, India

Raveendra Reddy, PATH, India

Sheila Reeves, USA

Alex Rehn, Australia

Lee Reichman, New Jersey Medical School, USA

Carolina Reigada, Brazil

Chandrakant Revankar, Individual-Consultant, USA

Marlise Richter, Wits University, South Africa

Andaleeb Rinquest, South Africa

Andrew Roberts, Australia

Caroline Robinson, RESULTS, United Kingdom

Celia Rodriguez, Spain

Bernice Roeland, Wellness Foundation -- AIDS Response, South Africa

Francisco Rosas, Vivir. Participacion, Incidencia y Transparencia, A.C., Mexico

Rosielma da Cruz RoseJìsúlè, Arcbo, Brazil

Victor Roy, GlobeMed, USA

Laia Ruiz Mingote, Planeta Salud, Barcelona

Stella Rumbam, World Vision PNG, Papua New Guinea

Careva Ruvinova, NGO Opcija Ohrid, Macedonia

Tomislav Ruzin, Healthy Options Project Skopje (HOPS), Macedonia

Memory Sachikonye, UK Community Advisory Board, United Kingdom

Kazeem Salami, University of Ilorin Teaching Hospital, Nigeria

Mónica Yvonne Salazar Angulo, DISA II Lima SUR, Peru

Mariia Samko, International Alliance HIV/AIDS , Ukraine

Vidya Sampath, India/USA

Ataulhaq  Sanaie, Anti Tuberculosis Association Afghanistan Program (ATA-AP), Afghanistan

Claudia Santos, Universidade Federal do Rio de Janeiro (UFRJ), Brazil

Valeria Saraceni, Brazil


Angela Savage, Australia

Carlos Savoie Pérez, Asociacón LGBTI Algarabía, Spain

Simon Schaaf, Desmond Tutu TB Centre, South Africa, South Africa

Gayle Schack, USA

Andrea Schaub, Australia

Samuel Schumacher, McGill University, Canada

Kevin Schwartzman, McGill University, Canada

Barbara Seaworth, Heartland National TB Center, USA

James Seddon, Desmond Tutu TB Centre, South Africa, South Africa

Vladlena Semeniuc, Moldova

Fadeev Sergey, bf Vektor dopomogi, Ukraine

Sarita Shah, Albert Einstein College of Medicine, USA

Debra Shelly, Community Research Advisors Group (CRAG), USA

Shiva Shrestha, PATH, India

Shobha Shukla, Citizen News Service (CNS), India

Billy Sichamba, Chichetekelo Outreach Partners, Zambia

Natalia Sidorenko, Russia

Carolina Silva, Secretaria Municipal de Saúde, Brazil

Maria das MercÍs Duarte da Silva, Brazil

Zulmira Silva, International Center for AIDS Care and Treatment Programs (ICAP) , Mozambique

Rajesh Singh, International Unnion Against Tuberculosis and Lung Diseases, India

Wallen Sinkala, Second Life Support Group, Zambia

Natalie Skipper, Community Research Advisory Group (CRAG), USA

Jason Smith, Australia

Andrea Smith, Australia

Alisha Smith-Arthur, University Research Co., LLC (URC),

Jussara Soares, Brazil

Rinn Song, Harvard Medical School, USA

Izabel S. de Souza Souza, Brazil

Jurema Souza, Universidade Federal do Rio de Janeiro, Brazil

Joel Spicer, Stop TB Partnership (STBP), Switzerland

Jeff Starke, Texas Children's Hospital, USA

Jonathan Stillo, The City University of New York , USA

Lucia Maria Stirbu, European AIDS Treatment Group (EATG), Romania

Quentin Stirling, Australia

Jayasankar Subramoniapillai, Revised National TB Control Program (RNTCP), India

Khairunisa Suleiman, Kenya/South Africa

Dan Sullivan, Bill Sullivan-Ray of Hope Foundation, USA

Honghu Sun, Sichuan University, China

Soumya Swaminathan, National Institute for Research in Tuberculosis, India, India

Bekana Kebede Tadese, University of Gondar, Ethiopia

Sabira Tahseen, National TB reference laboratory Pakistan, Pakistan

Elsa Tamrat, Australia

Alla Tannil, Estonian Network of People Living with HIV (EHPV), Estonia

Ivanir Tavares, Brazil

Ezio Tavora Santos-Filho, Rede TB, Brazil

Graham Thomas, Australia

Emma Tippett, Australia

Anna Tkacheva, Belarus

Olutoyosi Tokun, Nigeria

Anete Trajman, Brazil

Liudmila Trukhan, Positive Movement, Belarus

Evelyn Tsantikos, Australia

Thet Tin Tun, Burnet Institute Myanmar , Myanmar

Mary grace Tungdim, Department of Anthropology, University of Delhi, Delhi-110007, India

Nicole Turcotte, Gay Men's Health Crisis (GMHC), USA

Nonna Turusbekova, TBC Consult/HRM for Health, Netherlands

Ibrahim Umoru, Good Health Educators Initiative, Nigeria

Daniel Urrieta Salazar, Instituto Nacional De Salud, Peru

Mahalinga Raja Uthandaraman, India

Shanmugavel Uthandaraman, India

Gulnoz Uzakova, Global Fund to Fight AIDS, TB and Malaria , Uzbekistan

Emmy van der Grinten, KNCV Tuberculosis Foundation, South Africa

Wim Vandevelde, European AIDS Treatment Group (EATG), Europe

Ivan Varentsov, Eurasian Harm Reduction Network, Russia

Emanoil Vasiliu, Baylor International Pediatric AIDS Initiative (BIPAI), Romania

Vladislava Vassitškina, Estonia

Vituria Vellozo, Secretaria Municipal de Sa˙de e Defesa Civil do Rio de Janeiro, Brazil

Maria Elisa Verdú Jordá, Hospital Carmelo PNCTL, Mozambique

Eliane Vianna, Fundação Oswaldo Cruz (FIOCRUZ), Brazil

Treland Victoria, RESULTS Educational Fund, USA

Sofia Viegas, Instituto Nacional de Sáude, Mozambique

Asha Vijayan, Revised National TB Control Program (RNTCP), India

Shibu Vijayan, Global Health Advocates India , India

Michael Vjecha, USA

Fanny Voitzwinkler, Belgium

Stephen Volante, USA

Vlad Volchkov, International HIV/AIDS Alliance , Ukraine

Balasangameshwara Vollepore, FIND, India

Arne von Delft, TB Proof, South Africa

Dieter Von Hofmann, Australia

Bao Vu, PATH, Vietnam

Robert Wagner, Australia

Cornelia Wakhanu,

Nadene Walker, Australia

Dee Wallis, Australia

David Walmsley, Australia

Ibarakumo Brandon Walson, National Emergency Management Agency (South - South Zone), Nigeria

Eliud Wandwalo, Management Sciences for Health, Tanzania

Genevieve Warner Learmonth, University of Cape Town and Groote Schuur Hospital Cytopathology Laboratory, South Africa

Peter Watkins, Australia

Diana Weil, USA

Mariana Weinberger, Israel

Sally Whitaker, Australia

Matthew Whitbread, Australia

Desley Williams, Australia

Enid Williams, Australia

Jillian Wilson, Australia

Julie Wiltshire, Australia

Abimbola Esther Wintolu, PLAN Health Advocacy and Development Foundation, Nigeria

Emma Woods, Australia

Elizabeth Xipell, Australia

Abdullahi Yakubu Gida, TBL Control Programme, Bauchi, Nigeria

Mohammed Yassin, Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland

Joannes Paulus Yimbesalu, Cameroon

Keith Young, Australia

Thamer Yousif Al Hilfi, Iraqi Anti Tuberculosis Association, Iraq

Nadiia Zaiets, Estonian Network of People Living with HIV (EHPV), Estonia

Carlos Zamudio, Universidad Peruana Cayetano Heredia, Peru

Khin Zaw, Save the Children Myanmar, Myanmar

Ирина Агеева, Всеукраинская Сеть людей с ВИЧ, Украина

Кирилл Арсёнов, КО ВБО "Всеукраинская Сеть ЛЖВ", Украина

Чынара Бакирова, ОЮЛ "Ассоциация СПИД-сервисных НПО Кыргызской Республики ""АнтиСПИД"", Кыргызстан

Чынара Бакирова, ОЮЛ "Ассоциация СПИД-сервисных НПО Кыргызской Республики ""АнтиСПИД"", Кыргызстан

Юрий Боровой, The Association of Substitution Treatment Advocates of Ukraine (ASTAU), Ukraine

Ирина Галаченко, Молдова

андрей гуппал , эстония

Natalia Мardari, Credinta, Moldova

Игорь Морозов, клуб " свитанок, Украина

Анастасия Полякова, Россия

Ольга Пономарёва, клуб " свитанок, Украина

Ксения Проданова, КРУ"Центр профилактики и борьбы со СПИДом", Украина

Андрей Скворцов, The International Coalition Treatment Preparedness (ITPCru), Россия

Дмитрий Чехов, Украина

Оксана Ярош, ХОБФ"Парус", Украина